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A BST R AC T  
 
Aim: This study investigated the effect of antiepileptic drug monotherapy on cognitive functions in 
pediatric epilepsy patients.  
Methods: 98 recently diagnosed epilepsy patients aged 6-16 years were included. All patients 
underwent routine laboratory tests, electroencephalography, brain magnetic resonance imaging, and 
intelligence testing. The patients were treated with valproic acid (VA), carbamazepine (CBZ), 
oxcarbazepine (OXC), or levetiracetam (LEV). The Wechsler Intelligence Scale for Children (WISC-
R) was applied three times, before, six months and 12 months after the start of antiepileptic therapy.  
Results: No significant difference was determined among the mean verbal, performance and total 
intelligence scores of patients using a single antiepileptic drug at baseline, after six or 12 months. 
Conclusion:  We conclude that the type of antiepileptic drug using has no adverse effects on cognitive 
functions. 
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Introduction 
Epilepsy is the most common chronic, 
recurring neurological disease in childhood, 
and is an important public health problem 
[1,2]. Learning problems and low academic 
performance are the significant effects of 
epilepsy [3,4].  The primary aim of anti-
epileptic drugs for treatment of epilepsy is 
seizure control, and the secondary objective is 
to prevent cognitive disorders, thus avoiding 
potential future poor academic performance 
[5]. Antiepileptic drugs have both positive and 
adverse effects on cognitive functions, and 
these must be taken into account in the 
selection of anti-epileptics [1,3]. Various 
studies have reported that antiepileptic drugs 
impair cognitive functions in children [6-13], 
while other comparative studies have reported 
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no adverse effects of antiepileptic drug types 
on these functions [14-18]. However, there 
have been a few previous comparative, long-
term studies in children showing the effects on 
cognitive functions of antiepileptic such as 
valproic acid, carbamazepine, oxcarbazepine, 
and levetiracetam that are frequently today. 
This study investigated and compared the 
effects on cognitive functions of antiepileptic 
medications. 
 
Methods  
The study was performed between November 
2009 and June 2011 at the Erciyes University 
Medical Faculty Pediatric Neurology 
Department, Turkey. Approval for the study 
was granted by the Erciyes University Medical 
Faculty Ethical Committee (Decision no: 
08/112). Informed consent forms were 
obtained from patients’ parents. Ninety-eight 
newly diagnosed epilepsy patients in the 6-16 
age group, with no visual, hearing or speech 
problems, capable of reading and writing, with 
no other chronic disease and started on 
antiepileptic monotherapy any one of; valproic 
acid (VA) (20-30mg/kg/d), carbamazepine 
(CBZ) (20-25mg/kg/d), oxcarbazepine (OXC) 
(20-25mg/kg/d), or levetiracetam (LEV) (30-
40mg/kg/)) were included in the study. Patients 
aged 6-16 years diagnosed with epilepsy 
characterized by generalized tonic–clonic 
seizures or partial-onset seizures with or 
without secondary generalization were 
eligible. The diagnosis of epilepsy was based 
on clinical and electroencephalography (EEG) 
findings by two different pediatric neurologists 
according to the International League Against 
Epilepsy (ILAE) classification [19]. Before the 
initiation of antiepileptic therapy, all 98 
patients underwent routine laboratory tests, 
EEG, brain magnetic resonance imaging 
(MRI), and intelligence testing. 
Exclusion criteria included (1) signs of 
progressive neurodegenerative and metabolic 
disorders, (2) a history of major psychiatric 
disorders, (3) a history of alcohol or drug 
abuse, (4) a chronic medical illness, (5) 
ongoing use of any medication affecting the 
central nervous system, (6) a history of head 
injury with loss of consciousness, (7) visual or 
hearing disorders (8) previous exposure to any 
AED, (9) in whom seizure control had not been 
achieved, using more than one antiepileptic 
medications, (10) not attending regular follow-
up, and 11) older than 16 years old. 
Sociodemographic data forms were completed 
with the relatives of all patients enrolled. The 
Wechsler Intelligence Scale for Children 
(WISC-R) was applied three times in the 
evaluation of patients’ cognitive functions, at 
time of presentation before starting 
antiepileptic drugs, and after sıx and 12 months 
starting of antiepileptic use. We also inquired 
into seizure control. 
 
Wechsler Intelligence Scale for Children 
(WISC-R) 
WISC-R is one of the tests frequently used in 
research and to measure intelligence. The 
inclusion of examples from various skill areas 
in the subtests, the precision of the scoring and 
interpretation bases, and the satisfactory nature 
of the psychometric characteristics all 
contribute to the popularity of the scale. The 
Turkish-language standardization of the 
WISC-R meets the need for tests aimed at 
children [20].  
 
Statistical Analysis 
The data obtained were analyzed on SPSS 15.0 
for Windows software. Parametric statistical 
analysis methods were employed due to the 
adequate numbers of subjects and controls and 
to values being normally distributed. 
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Compatibility with normal distribution of 
quantitative data was assessed using the 
Kolmogorov-Smirnov normality analysis test. 
Normally distributed data were expressed as 
mean±standard deviation. Variation between 
drugs was analyzed using one-way ANOVA. 
The Scheffe procedure was used to identify the 
group representing the source of difference. 
Variation between two time periods (0, 6 and 
12 months) was examined using the Paired-t 
test, while variation among more than two time 
points was analyzed using Repeated Measures 
Analysis. The Bonferroni test was employed 
post hoc. Non-normally distributed data were 
expressed as median, and min-max. Variation 
between groups was evaluated using Kruskal-
Wallis Analysis of Variance. The Bonferroni-
corrected Mann Whitney U test was used to 
identify the group representing the source of 
difference. Variation between more than two 
time points was analyzed using the Friedman 
test. The Wilcoxon rank test with Bonferroni 
correction was employed to identify which 
group was different. Qualitative data were 
expressed as %. Variation between groups was 
analyzed using the Chi-Square test. 0.05 was 
regarded as representing statistical 
significance.  
 
Results 
Evaluation of gender and mean ages by 
medications is shown in Table 1, and mean 
verbal, performance and total intelligence 
scores in Table 2. The patients consisted of 53 
(54 %) boys and 45 (46 %) girls. Patients’ ages 
ranged between six and 16 years. The age for 
VA, CBZ, OXC and LEV cure groups was 
10.7±2.6, 11.5±2.8, 10.5±2.6 and 10.5±2.6, 
respectively.  
Mean verbal, performance and total 
intelligence scores were 91.3, 93.4 and 92.3 in 
girls and 90.5, 93.2 and 91.85 in boys, 
respectively. Three patients were excluded 
since seizure control could not be achieved at 
the end of six months. One patient was started 
on a second antiepileptic since seizure control 
could not be achieved at the end of 12 months, 
and two patients were excluded for 
discontinuing medication of their own volition. 
The study was thus completed with 92 patients.  
Brain MRI was performed in all patients and 
MRI results were pathological in 7 patients 
(arachnoid cist, nonspecific white matter 
lesions). 68 patients had generalize tonic clonic 
(GTC), 3 had juvenile absans type and 21 had 
focal seizures. 
 
Discussion 
No significant difference was observed in 
terms of cognitive functions between male and 
female patients using single antiepileptic. 
When valproic acid, carbamazepine, 
oxcarbazepine, and levetiracetam were 
compared among themselves and with baseline 
and six- and 12-month data, we again observed 
no significant variation between drug type and 
time points, and no adverse effects on 
cognitive functions. 
Malbourne and et al. [16] conducted a case-
control study of 33 Jamaican children with 
uncomplicated epilepsy and 33 of their 
classmates matched for age and gender to 
determine whether epilepsy resulted in 
differences in cognitive ability and school 
achievement and if socioeconomic status or the 
environment had a moderating effect on any 
differences. Intelligence, language, memory, 
attention, executive function, and mathematics 
ability were assessed using selected tests from 
NEPSY, WISCR, TeaCh, WRAT3 - expanded, 
and Raven's Coloured Progressive Matrices. 
They found that there was no significant 
difference in IQ, children with   epilepsy and 
their   controls.    This   study  was   conducted  
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without regard to the antiepileptic drugs used 
and there was no difference in the IQ 
comparison as in our study.  
In Taylor et al.’s [17] Standard and New 
Antiepileptic Drugs (SANAD) multi-center, 
randomized clinical study involving standard 
antiepileptic medications (carbamazepine and 
valproate) and novel antiepileptic (gabapentin, 
lamotrigine, oxcarbazepine and topiramate), 
222 epileptic patients underwent psychometric 
evaluation at three and 12 months, and no 
cognitive impairment was determined. 
However, the authors also reported a number 
of limitations, such as the lack of a control 
group, the heterogeneous nature of the study 
group, and that only 23% completed 
neuropsychological tests. Similarly to that 
study, we enrolled patients using the standard 
antiepileptic valproic acid and carbamazepine 
and the new antiepileptic oxcarbazepine and 
levetiracetam, and determined no significant 
difference in intelligence scores after six and 
12 months. Particular strengths of our study are 
that 91% of patients completed it and the 
homogeneous nature of the study group. Its 
limitations include the absence of a control 
group and a monitoring period of 12 months. 
In their prospective cohort study in which 407 
patients were monitored for 15 years, Sogawa 
et al. [18] compared patients with single 
unprovoked seizures with other epilepsy 
patients and reported only minimal long-term 
effects on educational cognitive activities. In 
this study, patients with seizure control 
established by a single antiepileptic drug were 
not compared with other epilepsy patients. The 
absence of impairment of cognitive functions 
in our single seizure patients may be linked to 
establishment of complete seizure control. 
 The cognitive effects of topiramate and 
levetiracetam were compared in newly 
diagnosed epilepsy patients in another study 
[21]. Cognitive complaints are common in 
topiramate treatment and frequently lead to 
drug withdrawal. The impact of levetiracetam 
on cognitive function is only mild. The 
difference in neurocognitive complaints was 
not statistically significant. Patients using 
topiramate were not included in our study, 
since it is not employed long term in our clinic 
due to its side-effects in children with epilepsy. 
No significant difference was determined 
when the cognitive effects of oxcarbazepine 
were compared with those of valproic acid, 
carbamazepine and levetiracetam in this study. 
In agreement with our study, another study 
investigating the cognitive effects of 
oxcarbazepine observed no significant effect 
on cognitive functions of one-year 
oxcarbazepine use [22]. 
Our findings were similar to those of another 
study reporting no significant adverse effect on 
cognitive functions at the end of one-year 
levetiracetam therapy [23]. However, the 
patients in our study were monitored, 12 
months, at the end of which we observed no 
impact on cognitive functions. 
A Randomized, double-blind, placebo-
controlled study showed positive effects in 
cognitive functions in epileptic children 
treatment with levetiracetam [24]. 
Our study include the lack of a control group, 
the follow-up period of 12 months, and that it 
was not multi-center research with a larger 
number of patients. A secondary limitation is 
that tests that can be used to assess cognitive 
functions have a number of difficulties in terms 
of reliability and applicability in Turkey. 
Moreover, there have been few comprehensive 
studies involving the antiepileptic drugs we 
commonly use and assessing cognitive 
functions in children. It is essential to consider 
how cognitive functions and academic 
performance may be affected when selecting 
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drugs for use in children with epilepsy. It is 
important to ensure that the antiepileptic that 
we determine will best achieve seizure control 
is also a medication that has a positive effect, 
or no adverse impact, on cognitive functions. 
We observed that the antiepileptic agents we 
frequently employ have no adverse impact on 
cognitive functions. However, further longer-
term and comprehensive are now required on 
this subject.  
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